VIDEO: Autoimmune Patient Discusses Concerns with Non-Medical Switching

July 8, 2016

In this video, patient advocate Kathleen Arntsen, President and CEO of the Lupus and Allied Diseases Association (LADA) and an autoimmune patient herself, discusses the power of advocacy and her concerns with Non-Medical Switching (NMS). NMS is the switching of a patient from one treatment to another, typically by a third party such as a Pharmacy Benefit Manager (PBM) […]

Read More

ASBM Presents at Latin American Forum on Biosimilars

July 6, 2016

On June 29th, ASBM Chairman Harry L. Gewanter, MD and ASBM Steering Committee Member Andrew Spiegel, Executive Director of the Global Colon Cancer Association, gave presentations at the 6th Latin American Forum on Biosimilars, held in Brasília, Brazil. The event was also the 7th Brazilian Forum on Biosimilars. The event was attended by more than 500 […]

Read More

Lupus and Allied Diseases Association: Affordable access critical for care

June 18, 2016

Biosimilar drugs hold advantages for people like me, just as biologic medicines have for millions living with life-threatening and life-diminishing diseases. Access to appropriate medication can dramatically improve disease outcome and quality of life. As more biosimilars become available, we want to ensure they are safe and affordable. I strongly support S6311 and A8648A, which […]

Read More

ASBM Presents to New York State Pharmacy Society

June 4, 2016

ASBM Presents to New York State Pharmacy Society  On June 3rd, ASBM’s Advisory Board Chair Dr. Philip Schneider, Associate Dean at the University of Arizona’s College of Pharmacy, presented to the Pharmacy Society of the State of New York (PSSNY) at a forum held at the Albany College of Pharmacy. Dr. Schneider discussed how biologics […]

Read More

CMS Biosimilars Rule: Rulemaking Malpractice

May 26, 2016

  by Kenneth Fisher, MD Nephrologist, ASBM Advisory Board Member Biologic medicines are one of the most powerful tools physicians have to treat patients with serious conditions like cancer, rheumatoid arthritis, hepatitis, and multiple sclerosis. Copies of these therapies, called biosimilars, are becoming available in the U.S., and offer patients new treatment options, potentially at […]

Read More

ASBM Presents to Nashville Pharmacy Students, Healthcare Practitioners

May 20, 2016

On Wednesday, June 15th, ASBM presented a one-hour educational program entitled “Biosimilars: New Choices, New Challenges” at TriStar Centennial Medical Center in Nashville, TN. Tristar Centennial educates pharmacy students from Belmont University, Lipscomb University, Murray State University, and the University of Tennessee, and the audience was comprised of 20 pharmacy students from these schools as well as nurse-practitioners […]

Read More

70 Stakeholder Groups Call on the FDA, Urging Distinguishable, Meaningful Suffixes for Biosimilars

May 11, 2016

WASHINGTON, DC—In a letter to the FDA this week, a 70-group coalition of healthcare stakeholders including patient and provider organizations and others urged the use of distinguishable, meaningful suffixes for biosimilars. The letter to Leah Christl, Ph.D., FDA’s associate director for therapeutic biologics, comes on the heels of FDA’s departure from a meaningful to random […]

Read More

ASBM Presents at PANLAR Conference

April 14, 2016

On April 13th, ASBM Chairman and pediatric rheumatologist Harry L. Gewanter presented to the XIX PANLAR Conference in Panama City, Panama, presented by the Pan American League of Associations for Rheumatology. More than 1000 physicians attended the conference representing countries in Latin America, South America, and the Caribbean. Dr. Gewanter shared data from ASBM’s global […]

Read More